RAS-F + RAS-F3

RAS-F + RAS-F3 appears to refer to an experimental small-molecule combination targeting RAS-family GTPases, likely building on an F3-scaffold series of pan-RAS inhibitors designed to disrupt RAS–effector interactions such as RAS–c-RAF and thereby inhibit downstream RAF–MEK–ERK and related signaling pathways in RAS-driven tumors.[1][4][5] Publicly available data specifically describing a defined drug product named “RAS-F + RAS-F3” are lacking; however, related compounds designated RAS-F and RAS-F3 have been described as small-molecule RAS inhibitors (RAS type GTPase family inhibitors) and pan-RAS F3-scaffold inhibitors in preclinical development for oncology, suggesting this denotes a research-stage combination of two closely related pan-RAS inhibitory molecules intended to more completely block oncogenic signaling.[1][4]